Globus Medical
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions increased by 19 in the most recent period (2026/Q3).
- Total institutional ownership rose 6.5 percentage points.
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 96.56% +6.46pp
- Institutions
- 721 +19
- As of
- 2026/Q3 vs. prior period
Holder types
Top holders as of 2026-03-31
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 28 buys · 21 sells
| Name | Role | Stake |
|---|---|---|
| David Paul | Co-Founder & Executive Chairperson | 16.85% |
| David Davidar | Independent Director | 0.51% |
| Ann Rhoads | Independent Director | 0.03% |
| Daniel Wolterman | Independent Director | 0.02% |
| Leslie Norwalk | Independent Director | 0.01% |
| Robert Douglas | Independent Director | 0.00% |
| John DeFord | Former Independent Director | -- |
| Stephen Zarrilli | Independent Director | -- |
| James Tobin | Independent Director | -- |
| Daniel Lemaitre | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-09 | James Tobin | Independent Director | Derivative Exercise and Sale | -41,666 | $43.58–75.68 |
| 2026-11-03 | Ann Rhoads | Independent Director | Automatic Disposition | -5,000 | $85.00 |
| 2026-09-14 | James Tobin | Independent Director | Derivative Exercise and Sale | -30,000 | $53.75–74.58 |
| 2026-08-17 | Stephen Zarrilli | Independent Director | Derivative Exercise and Sale | -25,000 | $53.27–87.04 |
| 2026-07-26 | David Davidar | Independent Director | Other Disposition | -2,500 | -- |
| 2026-06-04 | David Davidar | Independent Director | Derivative Exercise and Sale | -25,000 | $26.27–80.76 |
| 2026-06-03 | Ann Rhoads | Independent Director | Derivative Exercise and Retained | +25,000 | $26.27 |
| 2026-04-13 | John DeFord | Former Independent Director | Intent to Sell (Form 144) | -30,000 | $93.10 |
| 2026-02-24 | Kelly Huller | General Counsel | Derivative Exercise and Sale | -20,000 | $43.58–94.50 |
| 2026-02-11 | Kelly Huller | General Counsel | Derivative Exercise and Sale | -10,000 | $45.64–87.67 |
| 2026-01-20 | Ann Rhoads | Independent Director | Other Derivative Acquisition | +15,000 | $94.15 |
| 2026-01-20 | John DeFord | Former Independent Director | Other Derivative Acquisition | +15,000 | $94.15 |
| 2026-01-20 | Stephen Zarrilli | Independent Director | Other Derivative Acquisition | +15,000 | $94.15 |
| 2026-01-20 | James Tobin | Independent Director | Other Derivative Acquisition | +15,000 | $94.15 |
| 2026-01-20 | David Paul | Co-Founder & Executive Chairperson | Other Derivative Acquisition | +100,000 | $94.15 |
| 2026-01-20 | Daniel Wolterman | Independent Director | Other Derivative Acquisition | +15,000 | $94.15 |
| 2026-01-20 | Robert Douglas | Independent Director | Other Derivative Acquisition | +15,000 | $94.15 |
| 2026-01-20 | David Davidar | Independent Director | Other Derivative Acquisition | +15,000 | $94.15 |
| 2026-01-20 | Leslie Norwalk | Independent Director | Other Derivative Acquisition | +15,000 | $94.15 |
| 2026-01-20 | Daniel Lemaitre | Independent Director | Other Derivative Acquisition | +15,000 | $94.15 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Globus Medical discussion 0 comments